Back to results
US 2025/0026806 A1Published application
SIRPa VARIANT AND USE THEREOF
AssigneesHangzhou Sumgen Biotech Co., Ltd., Sumgen Mab (Beijing) Biotech Co., Ltd.
InventorsMing LV, Xiaoran DING, Shiwei MIAO, Bin TAN
Life of this patent
Estimating the term…
Abstract
Provided is a SIRPα variant and a fusion protein thereof, capable of specifically blocking interaction between CD47 protein and SIRPα, not causing coagulation reaction, and capable of inhibiting growth and/or proliferation of tumors or tumor cells.
Claims26
An SIRPα variant, comprising an amino acid substitution at the amino acid residue of N110, compared with a domain of the human SIRPα variant 1 or a fragment thereof.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.